Skip to content

Redefining humanly possible through the potential of muscle cell technology

Cook MyoSite is dedicated to commercializing muscle cell therapies and advancing the field of muscle cell technologies.
accent-top-left-1
accent-bottom-right-1
accent-top-left-2
Cook Myosite - 2024-131 Mobile
Cook Myosite - 2024-131

The most trusted name in muscle cell technology

Cook MyoSite was founded in 2002 to make regenerative medicine a part of everyday medicine. Since then, we’ve been working tirelessly to bring first-in-kind cell technologies to market with the most rigorous quality standards.

This dedication to quality extends to our Laboratory Research Services portfolio, manufactured under an ISO9001:2015 Certified Quality Management System.
bsi-iso-9001-certified
“The inventory of cells at Cook MyoSite is unrivaled, and it’s also more readily available than other suppliers. With MyoSite, there’s a PDF that gives all the details and makes life a lot easier when selecting cells. And as I said, the quantity of samples available is really helpful for designing experiments when we want multiple donors to compare.” 
Richard Day
Professor of Regenerative Medicine Technology, University College London
top-right
top-right-mobile
Cook Myosite - 2024-552 Mobile

Regenerative medicine can be everyday medicine

The Cook MyoSite mission began with a simple belief that the human body is capable of wonderful restorative potential. The investigational iltamiocel platform harnesses this potential by targeting the causes of muscle dysfunction, not just the symptoms.
Are you a physician interested in partnering?
Contact us
Cook Myosite - 2024-552
bottom-left
top-center
Cook Myosite - 2024-398
Cook Myosite - 2024-398 Mobile

Add some muscle to your research

Over 20 years of clinical development, Cook MyoSite has gained deep insight into muscle cell manufacturing, analysis, and culture. We offer the most reliable and highly characterized primary human skeletal muscle cells on the market, along with custom services to meet your particular research needs.

Our cells are manufactured under highly controlled conditions and cataloged to ensure future availability. Our cells are optimized for use with MyoTonic media products and come with expert support from Cook MyoSite research scientists.
CLINICAL RESEARCH SPOTLIGHT

DigniFI Fecal Incontinence Study: First Participant Treated

Cook MyoSite announced that the first participant was treated in the DigniFI Study, a two-stage, randomized, controlled Phase III trial comparing the safety and efficacy of iltamiocel with placebo in the treatment of female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury (OASI). The procedure was performed on August 19 at Segal Trials in Miami, FL, by Principal Investigator Steven E. Chavoustie, MD, FACOG, CCRP.